文献速递糖尿病

维拉帕米使用与新诊断糖尿病的减少相关

Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该回顾性人群队列研究利用台湾全民健康保险研究数据库(2000–2011年),比较口服维拉帕米与其他口服钙通道阻滞剂(CCB)成人新发2型糖尿病(T2DM)的发生率。维拉帕米组T2DM发病率为6.41/1000人年,其他CCB组为8.07/1000人年,校正后风险比(HR)为0.80(95%CI 0.68–0.94;P=0.006)。

要点

  • 维拉帕米组T2DM发病率为6.41/1000人年,其他CCB组为8.07/1000人年。
  • 维拉帕米使用与T2DM风险降低相关,校正HR 0.80(95%CI 0.68–0.94;P=0.006)。
  • 维拉帕米对65岁以上患者效果更显著(P<0.001)。

核心结论

  • 在无已知糖尿病史的患者中,与其他CCB相比,口服维拉帕米使用与新发T2DM发生率降低相关。

研究设计与样本

  • 回顾性人群队列研究,使用台湾全民健康保险研究数据库(2000–2011年),比较口服维拉帕米成人(4930例)与倾向评分匹配的口服其他CCB成人(4930例)。

主要发现

  • 随访期间,维拉帕米队列随访41958人年,新发T2DM 269例(4930例中);匹配队列随访42118人年,新发T2DM 340例(4930例中)。
  • 维拉帕米组T2DM发病率为6.41/1000人年,其他CCB组为8.07/1000人年。
  • 维拉帕米(对比其他CCB)与T2DM相关的校正HR为0.80(95%CI 0.68–0.94;P=0.006)。
  • 排除随访<180天或<365天的患者后,校正HR分别为0.79(95%CI 0.67–0.93;P=0.005)和0.77(95%CI 0.65–0.91;P=0.002)。
  • 仅年龄交互项显著(P=0.009),维拉帕米对65岁以上患者效果更显著(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The mechanism of the beneficial effect of calcium-channel blockers (CCBs), especially verapamil, on the development of type 2 diabetes mellitus (T2DM) has been described. This study compared the incidence of T2DM in adults prescribed oral verapamil and propensity score-matched adults prescribed other oral CCBs. METHODS: This retrospective population-based cohort study used Taiwan's National Health Insurance Research Database from 2000 to 2011. T2DM was defined according to the International Classification of Diseases, Ninth Revision, Clinical Modification. RESULTS: During follow-up periods of 41,958 and 42,118 person-years, 269 of 4930 patients in the verapamil cohort and 340 of 4930 patients in the matched cohort, respectively, developed T2DM. The incidence rates were 6.41 and 8.07 per 1000 population per year among verapamil and other CCB users, respectively. The adjusted hazard ratio (HR) for T2DM associated with use of verapamil (vs. other CCBs) was 0.80 [95% confidence interval (CI), 0.68 to 0.94; P = 0.006]. After exclusion of patients followed for <180 days or <365 days (to avoid bias derived from delayed diagnosis), adjusted HRs remained significant [0.79 (95% CI, 0.67 to 0.93; P = 0.005) and 0.77 (95% CI, 0.65 to 0.91; P = 0.002), respectively]. Only the interaction term for age was significant (P = 0.009). Verapamil had a more prominent effect on patients aged older than 65 years (P < 0.001). CONCLUSIONS: In patients with no known history of diabetes mellitus, oral verapamil use was associated with a decreased incidence of T2DM compared with other CCBs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yin T, Kuo SC, Chang YY, et al. Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus. J Clin Endocrinol Metab. 2017. PMID: 28368479. doi:10.1210/jc.2016-3778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。